A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy and Safety of LY3041658 in Adults With Moderate-to-Severe Hidradenitis Suppurativa
Latest Information Update: 30 Apr 2023
At a glance
- Drugs Eltrekibart (Primary)
- Indications Hidradenitis suppurativa
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 12 Dec 2022 Status changed from active, no longer recruiting to completed.
- 06 Apr 2022 Status changed from recruiting to active, no longer recruiting.
- 15 Oct 2021 Planned End Date changed from 7 Apr 2022 to 2 Nov 2022.